Synthesizing the early clinical data presented for TCEs targeting PSMA, STEAP1, and DLL3 (Table 1), a compelling picture emerges: T-cell engagers possess the intrinsic capability to elicit meaningful anti-tumor activity in heavily pretreated mCRPC patients, a population often refractory to standard therapies. The gene discussed is STEAP1; the disease is neoplasm.